Cell-cycle control and renal disease  by Shankland, Stuart J.
Kidney International, Vol. 52 (1997), pp. 294 —308
PERSPECTIVES IN BASIC SCIENCE
Cell-cycle control and renal disease
STUART J. SHANKLAND
Division of Nephrology, Department of Medicine, Universily of Washington, Seattle, Washington, USA
The earliest investigators looking through primitive micro-
scopes to study the pathology of renal disease recognized that an
excess of cells was a central feature of many glomerular diseases,
particularly those with a prominent inflammatory component.
Although it was initially thought that glomerular hypercellularity
resulted primarily from invasion by circulating inflammatory cells,
the much later recognition of the three separate intrinsic glomer-
ular cell types and development of more sophisticated immuno-
histochemical techniques for identifying them made us aware that
much of the increased cellularity in glomerular disease resulted
from proliferation of these intrinsic cell populations [1]. The
stimuli for proliferation in response to glomerular injury have
been defined both in vitro and in vivo and involve exposure to
growth factors, cytokines, complement components and other
mitogens [reviewed in [2, 31. More recently appreciated are the
potential consequences of glomerular and tubulointerstitial cell
proliferation that involve the overproduction of other cytokines
and growth factors setting up autocrine mechanisms of injury,
release of mediators such as oxidants and proteases that damage
glomerular basement membrane, and the overproduction of ex-
tracellular matrix proteins leading eventually to sclerosis and
renal failure [reviewed in I. Indeed, a link between proliferation
of mesangial cells and subsequent glomerular sclerosis has now
been established in various forms of injury including glomerulo-
nephritis [5], glomerular hypertension [6] and diabetes [71,which
comprise the three major causes of end-stage renal disease in the
US. A similar link between interstitial cell proliferation and renal
fibrosis has been suggested as well [8, 91.
These advances in the cell biology of glomerular and tubuloin-
terstitial disease have been accompanied by a parallel increase in
understanding of the basic mechanisms that regulate cell division.
A resting cell integrates extracellular signals, and the proliferative
response reflects a balance of mitogenic and anti-proliferative
forces. Proliferation is controlled at multiple levels, including
cytokines and their receptors, intracellular signaling pathways
(such as the mitogen-activated protein kinase, protein kinase A
and C pathways) and nuclear events (for example, early and late
response genes) [10]. In the past few decades it has been
recognized that a cell has to engage the cell cycle to proliferate.
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This was followed by the discovery of specific cell-cycle proteins
required for transition through the cell-cycle. In the past few years
excitement has focused on the processes required for engagement
and transition through the cell-cycle. While it has been well
recognized that DNA synthesis and cell division required for cell
proliferation are ultimately regulated at the level of the cell-cycle,
the specific interplay of the cell-cycle regulatory proteins is an
area of research that is now developing rapidly. This article will
review the biology of the cell-cycle regulatory proteins, how they
are regulated by cytokines, and what is known about their
expression and role in renal disease.
THE CELL-CYCLE
To proliferate, a cell must enter the cell-cycle where DNA
synthesis and mitosis occur [reviewed in 11]. Under appropriate
mitogenic stimuli, cells exit quiescence (also known as GO), and
enter the cell-cycle at the level of early Gi phase (Fig. 1) [12].
Cells transit through Gi phase of the cell-cycle, where in late Gi
they pass through the "restriction point" [13], and thereafter the
cell is no longer responsive to extracellular signals, and is com-
mitted to completing the cell-cycle independent of mitogenic
stimuli. Cells transit through GuS into the S phase of the
cell-cycle, where DNA synthesis occurs. The S phase is followed
by the G2 phase, and the final phase of the cell-cycle is mitosis (M
phase) where nuclear division occurs. This organized progression
through the cell-cycle ensures that DNA replication occurs only
once in each cycle, and that DNA replication is completed before
mitosis occurs.
Although the duration of the cell-cycle is cell-type specific, only
the duration of Gi can be altered, whereas the duration of the
subsequent phases of the cell-cycle are fixed. Thus, in a typical
animal cell-cycle Gi lasts 12 hours, S phase six hours, G2 lasts six
hours, and mitosis occurs in 30 minutes [14]. During transition
through the cell-cycle, a cell can be arrested at a number of
specific "checkpoints" typically at GuS and G2/M (Fig. 1) [re-
viewed in 15, 16]. Cell-cycle arrest prevents completion of the
cell-cycle, and hence proliferation. Progression through the cell-
cycle is controlled by a group of intricately linked nuclear pro-
teins, known as cell-cycle regulatory proteins. Both positive
regulatory cell-cycle proteins (cyclins and cyclin-dependent ki-
nases) and negative regulatory cell-cycle proteins (cyclin-kinase
inhibitors) are involved.
In addition to cell proliferation, entry into the cell-cycle is also
associated with other events as shown in Figure 2. For example,
cells can exit at any phase of the cell-cycle by undergoing
programmed cell death (apoptosis) [17, 18]. Cells can undergo
senescence, in which they are permanently growth-arrested and
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Fig. 1. Schematic diagram of the cell-cycle. Cells exit from quiescence
(GO) and enter the cell-cycle at the level of early Gi, and transit through
late GuS. DNA synthesis occurs during the S phase, which is followed by
G2 and mitosis (M phase) where cell division occurs. The restriction (R)
point is where cells commit to completing the cell-cycle. Cell-cycle arrest
can occur at either the 01/S or G2/M checkpoints.
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Fig. 2. Under appropriate stimuli a quiescent cell enters the cell-cycle,
which leads to cell proliferation. Once in the cell-cycle, a cell can exit by
undergoing apoptosis or can complete a cycle, but becomes unresponsive
to mitogens because they have become either senescent or terminally
differentiated. Uncontrolled transition through the cell-cycle is a charac-
teristic of neoplastic transformation.
no longer respond to mitogenic stimuli [19]. In contrast, cells
entering the cell-cycle can also become terminally differentiated
(committed) into specialized cell types such as the mesangial cell
and glomerular epithelial and endothelial cells, where they still
maintain the ability to re-enter the cell-cycle only under appro-
priate stimuli. Finally, uncontrolled transit through the cell-cycle
is a characteristic feature of neoplastic transformation [20]. Thus,
the decision to undergo proliferation is a complex one, and is
governed by the balance of positive and negative cell-cycle
regulatory proteins. The following describes what is currently
known about these proteins, particularly as they relate to renal
cells and renal disease.
CYCLINS AND CYCLIN-DEPENDENT KINASES: POSITiVE
REGULATORS OF THE CELL-CYCLE
The current model explaining the events involved in initiating
and maintaining progression through the cell-cycle is that a
regulatory protein, the cyclin, forms an active complex with a
catalytic subunit, the cyclin-dependent kinase (CDK) (Fig. 3 and
Table 1) [15]. Cyclins and CDKs are located within the nucleus.
Each cyclin-CDK complex is expressed in specific phases of the
cell-cycle, and are required for transition from one phase to
another (Fig. 3).
('yclins
This diverse family of nuclear proteins is defined on the basis of
sequence homology that is limited to a relatively conserved
Fig. 3. Cyclin—cyclin dependent kinase (CDK) complexes. Progression
through the cell-cycle is dependent on phase specific cell-cycle regulatory
protein interactions. In early GI, D-type cyclins complex with CDK4 or
CDK6, while in late GI cyclin E complexes with CDK2. Cyclin A
associates with CDK2 in S phase and G2 phase, and Cyclin B complexes
with cdc2 (cell division cycle gene 2) during mitosis.
Table 1. Cell-cycle regulatory proteins
Cell-cycle
phase Cyclin Partner CDK Associated CM
GI Dl, D2, D3 CDKs 2, 4, 5, 6 p15, p16, p18, p19,
p21, p27, p.17
GuS E CDK2 p21, p27, p17
S A CDK2 p21, p27, p.17
M A
B
cdc2(CDK1)
cdc2(CDK1)
p21, pZ7, p17
p17
domain of approximately 100 amino acids, known as the "cyclin
box" (Table 2). The latter is responsible for the cyclin binding to
its specific subcatalytic partner, the cyclin-dependent kinase
(CDK) [20]. Cyclins are named A through H, and each cyclin is
required for transition through a specific phase of the cell-cycle
[reviewed in 33]. Cyclins are regulated transcriptionally and post-
translationally, and cyclin levels fluctuate throughout the cell-
cycle, reflecting the proliferative status of the cell (Table 1) [34].
D-type cyclins. The early GI phase cyclins are named D-type
cyclins, which include cyclin Dl, D2 and D3 [33]. The D-cyclins
are independently regulated, and have differences in tissue distri-
bution and behavior during the cell-cycle and differentiation [23,
24, 35]. They also differ in their interaction with the primary
target, the retinoblastoma protein [36]. Together, these features
suggest that the D-type cyclins are not redundant. D-type cyclin-
CDK complexes phosphorylate and thereby inactivate retinoblas-
toma protein [37], an event associated with GuS transition (see
below). The D-type cyclins and their CDK partners can also form
complexes with proliferating cell nuclear antigen (PCNA), a DNA
polymerase auxillary protein that is required for cell proliferation
[38], and is often used as a marker of cell proliferation in renal
disease. The induction of D-type cyclins is growth factor depen-
dent [39, 40] and the levels for D-type cyclins decrease on growth
factor withdrawal [39, 40]. A number of factors such as TGF-131
[411 and cAMP [39] inhibit D-type cyclins, and inhibition is
associated with the failure of quiescent cells to enter the cell-cycle,
indicating that these cyclins are required for GO/Gi transition
[42]. The D-type cyclins also determine the duration of 01.
Overexpression of cyclin Dl, D2 and D3 shortens the Gi phase of
the cell-cycle [35, 43], while microinjections of antibodies against
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Table 2. Characteristics of cell cycle regulatory proteins
Cell-cycle protein Conserved domain Shared homology
Cyclins Cyclin box [21] TATA-less promoters [23—25]
PEST domain in cyclin D and E [261
Cyclin-dependent kinases PSTAIRE region [22]
Cyclin-kinase inhibitors
Cip/Kip family N-terminus CDK binding domain [16] 1. p21 and p27: 44% homology in a 60 amino-acid
segment in N-terminus [27]
2. p27 and p57: in C-terminus both have consensus
sequence rich in proline (28%) and acidic segments
(37%) called the QT domain [28]
INK family Ankyrin repeats [16] 1. p15 and p16: 44% homologous in first 50 amino
acids and 95% in last ankyrin domains [29, 30]
2. p18 shares 38% protein sequence with p16 and 42%
with p19 [31]
cyclin Dl or antisense to cyclin Dl RNA blocks progression
through Gi [42, 44]. The induction of D-type cyclins is therefore
a possible mechanism whereby growth factors and other mitogens
initiate GO/Gi entry into the cell-cycle and progression through
the cell-cycle [45].
Cyclin E. Cyclin E is expressed in the late Gi phase of the
cell-cycle, and expression is increased by mitogenic growth factors
and cytokines [46] and in certain tumors [471. Overexpressing
cyclin E shortens Gi and decreases the requirement for growth
factors [46]. Furthermore, cyclin F determines the rate of GuS
transition [48], but is not required for DNA synthesis. Cyclin E is
also the target of TGF-/31 [41, 49, 50], which inactivates the cyclin
E-CDK2 kinase complex leading to cell-cycle arrest in GI, Both
D-type cyclins (the free form of cyclin Dl has a T1/2 of 10 minutes
[45]and the bound form has a T1/2 of 25 minutes [51]) and cyclin
E are very unstable and have short half-lives [52].
Cyclin A. Levels of cyclin A increase in the late Gi phase, and
peak in S and G2, where they form complexes with CDK2 and
cdc2 (cell division cycle gene 2, formerly known as CDK1),
respectively [53]. Cyclin A is required for the onset of DNA
synthesis and also for ongoing DNA synthesis [541. Cyclin A can
also affect GuS transit, as overexpression of cyclin A overcomes
GuS block induced by loss of cell adhesion [55]. During the S
phase, cyclin A also forms a complex with the transcription factor
E2F which in turn regulates a number of growth-promoting genes
[56, 57]. Cyclin A expression is decreased under certain circum-
stances such as contact inhibition [58] and by TGF-131 [58—60]. It
is interesting to note that the inhibition of cyclin A-dependent
CDK2 activity by TGF-pl requires the presence of both TGF-/3
type I and type II receptors [611. Recent studies have identified a
TGF-13 responsive sequence in the cyclin A promoter [61].
Cyclin B. Cyclin B synthesis commences in the S phase, and is
expressed during the late G2 and M phases where it binds to cdc2
[62, 63]. Cyclin A and cyclin B are regarded as regulators of the
transition to mitosis. The short half-life for cyclins A and B
(approximately 20 mm) is due to increased degradation, which is
mediated through the ubiquitin system [25, 64, 65]. CDK7, which
complexes with cyclin H, is part of cyclin activiating kinase, and is
required for proliferation [46, 661. Less is known about the cyclins
C, F and G.
Cyclin-dependent kinases
Cyclin-dependent kinases (CDK) are numbered CDK2 to
CDK7 [15]. Historically, cdc2 was formerly called CDK1. CDKs
are serine/threonine kinases that are closely related in size (35 to
40 kDa) and share >40% homology due to a sequence known as
the PSTAIRE region [221. The typical catalytic subunit contains a
300 amino acid core that is completely inactive when in a
monomeric (unbound to a cyclin) and unphosphorylated form
[67]. Cyclin-dependent kinases that are not bound by a cyclin are
inactive. Activation of a CDK (Fig. 4) is dependent on: (a) the
CDK complexing to a specific cyclin [68]. Each CDK binds to one
or more specific cyclins to form an active cyclin-CDK complex
(Table 1); (b) the dephosphorylation of Thr 14 and Tyr 15 by a
specific phosphatase [69]; (c) phosphorylation of a conserved
threonine residue (Thr 160) by the enzyme cyclin activating kinase
(CAK) (Fig. 4) [66, 70] accounts for the catalytic activity of CDKs
being regulated primarily post-translationally [63] (CDK5 protein
levels tend to remain constant throughout the cell-cycle); (d) the
removal of cyclin kinase inhibitors (CM), or an increase in
cyclin-CDK expression and activity sufficient to overcome the
inhibitory threshold of CM [161.
Crystallography studies have identified an interaction between
the PSTAIRE region on the CDK and the "cyclin box" of the
partner cyclin, which form the cyclin-CDK interface. Cyclins
associate with specific CDK catalytic subunits in a phase depen-
dent manner where the D-type cyclins bind to several different
CDKs, CDK2, CDK4, CDK5 and CDK 6, of which CDK4 and
CDK6 are the main partners. Therefore, D-CDK complexes are
required for GOIG1 transition and early Gi progression [15, 71].
Cyclin E associates with CDK2 [46] and perhaps CDK3 and is
required for GuS transition, cyclin A complexes with CDK2 for
DNA synthesis and mitosis [54], while cyclin B complex with cdc2
for mitosis [72].
Inactivation of CDK (Fig. 4) can occur by (a) a decrease in the
levels of cyclins [65]; (b) phosphorylation of the Thr 14 and Tyr 15
by the kinases weel/miki; (c) dephosphorylation of Thr 160; (d)
TGF-f31 [50, 731; or (e) the binding of a cyclin kinase inhibitor
(CM) to the cyclin-CDK complex [74] (see below).
RETINOBLASTOMA PROTEIN: A SUBSTRATE FOR
CYCLIN-CDKS AND REGULATOR OF GuS TRANSITION
To understand the role of cyclins and CDKs in cell-cycle
progression, one should consider a model whereby there is a
sequential activation of CDK by specific cyclins. The TATA box is
a motif in the promoter of certain genes that is required to fix the
site of transcription initiation. The promoters of the cyclin Dl
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receptor
Fig. 4. Schematic diagram of cyclin-CDK
complex activation and deactivation. Unbound
cyclins and CDK are inactive. Cyclin binds to
specific cyclin-dependent kinases (CDK),
forming a cyclin-CDK complex. In the case of
CDK2 (shown in this example), kinase activity
is also dependent on the phosphoiylation of
Thrl6O by the enzyme cyclin activating kinase(CAK), and the dephosphoiylation on other
residues by cdc25 phosphatases. Inhibiton of
kinase activity results from the disruption of the
cyclin-CDK complex by cyclin kinase inhibitors
(CM), phosphorylation of thrl4 and tyrl5 by
wed and miki kinases, and the
dephosphorylation of thr 160.
Fig. 5. Schema showing how mitogenic
cytokines engage cell-cycle regulatory proteins.
The binding of a mitogen to its receptor on the
cell surface is followed by various intracellular
signaling pathways (such as mitogen-activated
protein kinase, protein kinase A and C
pathways), and these signals converge on the
nucleus. This results in the induction of early
response genes such as fos, jun and myc. The
early response genes direcly increase the
expression of cyclins and cyclin-dependent
kinases (CDK). Mitogens can also decrease the
expression of certain cyclin-kinase inhibitors
(CKI) such as p27KIP1 by as yet unknown
mechanisms. The increased cyclin-CDK
expression and activity and the reduced CM
expression lead to the phosphorylation of pRb,
which allows GuS transition and DNA
synthesis.
[23], cyclin D2 [24], cyclin D3 [24], cyclin A [25] and CDK2 [75]
are all TATA-less and therefore have multiple binding sites for
early response genes such as fos, Jun and myc [76]. However,
although cyclins and CDKs are critical for DNA synthesis and
mitosis, it is important to recognize that the regulation of these
events by these cell-cycle proteins actually occurs through a
number of target proteins [26, 77], Perhaps the best known
example is the retinoblastoma protein (pRb), a Gi substrate,
which has been referred to as the "gatekeeper of GuS transition"
[reviewed 78]. In its hypophosphorylated (growth-inhibitory) form
that may be induced by TGF-pl [79], pRb binds to the transcrip-
tion factor E2F, and thereby prevents GuS transition [80]. In
contrast, phosphorylation of pRb (growth-permissive form) by
cyclin-CDK is associated with the release of E2F. E2F then binds
to genes involved in DNA synthesis such as dihydofolate reduc-
tase, c-myc and DNA polymerase [81]. Taken together, cyclin-
CDKs act on downstream targets to induce DNA synthesis (Fig.
5).
CYCLIN-KINASE INHIBITORS: NEGATIVE REGULATORS
OF THE CELL-CYCLE
Progression through the cell-cycle can be arrested at one of two
"check points." The first is the GuS checkpoint (not to be confused
with the restriction point in late Gi), which prevents cells that
sustained DNA damage in Gi from DNA replication in the S
phase. The second checkpoint is at G2/M, which prevents cell
entry into mitosis if DNA damage occurred in G2 [75]. Cyclin-
kinase inhibitors (CM) are nuclear proteins that are the major
regulators of these cell-cycle checkpoints (reviewed [16, 831. CKI
bind tightly to cyclin-CDK complexes, thereby preventing phos-
phorylation of the retinoblastoma protein and other unidentified
substrates, which in turn leads to cell-cycle arrest. CKIs are named
by their protein molecular weight, and are classified according to
sequence homology and substrate specificity (Table 3). Two
families of CM have been identified (Table 1) The first family is
the Cip/Kip family and comprise p21CIP1. WAF1. SDII. CAP2O,
p27''1 and p572, which inhibit cyclin-CDK complexes both in
Inactive Active
Cyclin CAK Cyclin
CDK cdc25 ______
phosphatase
c;II:IIII:;2016O
thrl4 tyrl5
CKI
weel/miki
Inactive
Cyclin
CDK
P P thrl6O
thrl4 tyrl5
Cell
Mitogenic cytokine I Growth factor
membrane
Cytoplasmic signaling '\
pathways
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genes ?
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Cyclin-CDK
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Table 3. Cyclin kinase inhibitors
CKI Synonym Chromosome Regulation Highest level Increased Target yclin-CDK
p15 INK4a, MTS2 9p21 Transcription TGF-f31 induced
growth arrest
TGF-131 [291 D-CDK 4,6 [29]
p16 TNK4b, MTSI 9p2i Transcription No change throughout
cell-cycle
Tumors [85] D-CDK 4,6 [30, 98]
p18 INK4c lp32 Transcription S phase D-CDK 4,6 [99]
p19 INK4d Transcription S phase D-CDK 4,6 [311
p21 CIPI, 6p2l.l Transcription Proliferation, terminal p53 [86] D-CDK 4,6; E-CDK2,
WAF1, differentiation TGF-131 [87, 90] A-CDK2 [100, 101]
SDII, Differentiation [91, 93]
CAP2O Mitogens [94]
p27 Kipi l2p12, 12pl3 Translation Quiescence [84] TGF-/31 [27],
rapamycin [95],
cAMP [961
D-CDK4,6; E-CDK2,
A-CDK2 [27]
p57 Kip2 Transcription Tumors [97] D-CDK4,6; E-DK2,
A-CDK2 [28, 102]
a MTS, multiple tumor suppressor
the Gi and S phases of the cell-cycle. The second family of CKJ
is called the INK4 family of inhibitors (which include p15, p16,
p18 and p19) and inhibit only D-type cyclin-CDK complexes.
Two possibilities may explain how CKI inhibit kinase activity.
First, binding of the CKT disrupts or blocks the binding of a cyclin
to the CDK [74]. Second, the CKI can block phosphorylation of
Thrl6O on CDK2 [1031 and Thr172 on CDK4 [96] by inhibiting
CAK.
CIP/KIP FAMILY OF CM
All three members of the Cip/Kip family (p21, p27 and p57)
share significant sequence homology through a CDK-binding
domain at the N-terminus, required for inhibiting both the Gi and
S phase cyclin-CDK complexes (Table 1), and less strongly cyclin
B-containing complexes [104]. In contrast, each member has
different structural and functional properties at the C terminus.
Overexpression of p21, p27 or p57 is sufficient to induce cell-cycle
arrest in Gi in vitro in various cell types [105].
p2!
The CM p21 is known by a number of different names (Table
3) because it was discovered in several laboratories using com-
pletely different approaches. These include p21 as a CDK inhib-
itor (Cipi, or CDKinhibitingprotein 1 [100, 106], as a protein that
inhibits CDK2 (CAP2O, CDK2-associated protein-20 [107]), as a
gene that is regulated by p53 (WAF1, wild-type p53-activated
fragment 1 [86]), and as a protein that prevents senescent cells
entering the cell-cycle (SDI1, senescent cell-derived inhibitor
[108]).
p21 can inhibit cell proliferation by two independent and
functionally distinct mechanisms. The first is by inhibiting CDK2
through the CDK-binding domain in the N-terminus [100, 104,
105, 1091. Second, p21 has a PCNA-binding domain in the
C-terminus [109, 1101. Proliferating cell nuclear antigen (PCNA)
is an auxillary protein to DNA polymerase required for DNA
synthesis [111] and nucleotide excision repair of DNA [112].
There are six binding sites for p21 per PCNA trimer [113].
Therefore, p21 can form either a quaternary complex with PCNA,
cyclin and CDK, or p21 can bind to PCNA directly [97, 105, 109,
110, 114]. Thus, p21 can inhibit proliferation by inhibiting CDKs
V
Gi arrest
Fig. 6. Association of p53 and p21. The expression of p53 increases
following DNA injury, and is responsible for DNA repair and apoptosis.
p53 causes cell-cycle arrest by direcly increasing the expression of p21
(WAF1, CIP1, SDI1, CAP1). The anti-proliferative cytokine transforming
growth factor-/31 (TGF-f31) also increases p21 levels. p21 associates with
proliferating cell nuclear antigen (PCNA) to prevent DNA synthesis and
inhibits cyclin-cyclin dependent kinase (CDK) complexes to cause Gi and
GuS arrest. Other cyclin-kinase inhibitors are not regulated by p53.
or PCNA. Overexpression of p21 in vivo also inhibits proliferation
in a model of balloon angioplasty [1151.
p21 is absent during quiescence and levels are transcriptionally
regulated [95]. p21 expression is closely linked to the tumor
suppresser gene p53 [861. In addition to its critical role in
apoptosis, p53 is also required for cell-cycle arrest in response to
DNA damage (Fig. 6). For example, DNA damage following
irradiation is associated with the induction of p53, which in turn
directly up-regulates the expression of p21, which causes cell-cycle
arrest [116]. This is because the promoter region of p21 has two
p53-binding consensus sequence sites [117]. Therefore, p21 is an
important effector of the growth suppressive function of p53 [86].
DNA repair
— _
Apoptosis
p53—
+
TGF-131 — —
0-type
cyclins
$
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DNA synthesis
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Shankland: Cell cycle proteins and the kidney 299
Interestingly, p21 is also regulated by p53-independent pathways
[94]. For example, because the p21 promoter region has a binding
domain for TGF-f31, p21 transcription is increased by TGF-f31
independent of p53 187, 88].
p21 expression also correlates with cell-cycle withdrawal during
terminal differentiation in a variety of cell types, and this is
p53-independent [91—93, 118]. However, mice homozygous for a
null mutation in the p21 gene develop normally and do not
demonstrate increased tumorigenesis [119, 120]. Mice transgenic
for p21 have increased hepatic fibrosis, suggesting that appropri-
ate levels of p21 are critical for normal liver development [121].
p27
The cDNA for p27 was cloned independently using protein
sequence information [271 and the two-hybrid system [122]. Like
other members of this CKI family, p27 has a CDK-binding
domain in the N-terminus, which binds to and inhibits cyclin D-,
E-, A-, and B-dependent kinases (Table 3). In contrast to p21, p27
does not bind PCNA and is not regulated by p53. However, p27
and the related CM, p57, share some homology (Table 2).
Because p27 is not under transcriptional control, the mRNA
levels are unchanged during the cell-cycle [123]. In contrast to
p21, the protein levels for p27 are high in most quiescent cells,
where p27 is in excess of cyclin-CDK complexes [27, 84]. p27
levels then decrease during proliferation [95]. The rate of p27
translation is increased in growth-arrested cells where the half-life
for p27 is 2.5 hours, supporting the notion that translational
control is partially responsible for the changes in p27 levels
throughout the cell-cycle. Another possibility is that p27 levels are
regulated by its turnover. Degradation of p27 occurs through the
ubiquitin pathway [124]. In quiescent cells following growth factor
withdrawal there is a smaller amount of p27 ubiquitinating
activity, which may account for the longer half-life measured in
these cells [124]. Taken together, p27 levels reflect both transla-
tion (protein synthesis) and degradation (protein breakdown).
Thus, the finding that quiescent cells express p27 and levels
decline on entry into the cell-cycle suggests that p27 may regulate
quiescence. Sherr and Roberts have proposed that the basal
amount of p27 expressed in proliferating cells may contribute to
an inhibitory threshold imposed on CDK activation during Gi
[16]. This notion was later supported by studies where the levels of
p27 were reduced in cells by using specific p27 antisense oligode-
oxynucleotides. Cells transfected with p27 antisense oligode-
oxynucleotides did not undergo Gl arrest after serum withdrawal
[125]. Coats also showed that the length of GI is dependent on the
amount of p27 expressed, and that restriction point control
requires p27 [1251. More recently it has been appreciated that
cyclin-kinase inhibitors p21 and p27 are critical in the cell's
proliferative response to mitogens (Table 3). There is a paradox-
ical expression of p21 and p27 during cell proliferation where
proliferation is associated with a decline in p27 levels and an
increase in p21 levels. The reason for the increase in p21
expression remains to be fully elucidated. Sherr and Roberts have
suggested that for mitogens to induce cell proliferation, the levels
of cyclin-CDK complexes must exceed the levels of the CM, and
that the kinase activity has to exceed the inhibitory threshold set
by the CM [16].
The role of p27 in vivo has recently been described indepen-
dently by three different groups studying p27 knockout mice
[126—128]. Mice lacking p27 have increased body size compared
to p27 wild-type litter-mates, and the increase is due to an
increase in cell number in all the organs studied. In collaboration
with J.M. Roberts, we have shown that the kidneys of these
animals are increased in size compared to wild-types, and this is
due to increased cell number. However, there is no increase in
staining for PCNA or BrdU in the adult mouse kidney (personal
observation).
p57
The most recently identified member of the Cip/Kip family is
p57, which also contains an N-terminal CDK inhibitory domain
and has sequences similar to p27 in the C-terminal end. However,
because it contains four distinct regions, p57 is the most structur-
ally diverse member of this family. p57 also inhibits GuS cyclin-
CDK complexes similar to other members of this family, except
that p57 has reduced affinity for cyclin D2-CDK6 [102]. p57 has
tissue specific patterns of expression [28] and the expression
partially overlaps with that of p21 during mouse development
[102]. Because of its association with numerous cancers, p57 may
be a tumor suppressor gene, but further studies are required to
support this [102].
INK4 FAMILY OF INHIBITORS
The second family of CM is the INK4 (inhibitor of cdk4)
family, which comprise p16, p15, p18 [99], and p19 (Tables 2 and
3) [31]. These are structurally related proteins, each containing
four ankyrin-like repeats that are important for interaction with
the CDKs [29, 30]. Furthermore, there is homology between
individual members of this family (Table 2). In contrast to the
Cip/Kip family of CM, inhibition of cyclin-CDKs by the INK
family of CM is restricted to cyclin D-CDK4 and cyclin D-CDK6
complexes [30]. Of interest is that p16 and p18 can only arrest cells
containing functional pRb [99]. The INK4 CM can also bind
preformed cyclin D-CDK4 or CDK6 complexes, and likely also
inhibit the interaction of the kinase complex with their substrates
[129]. Although the INK4 family are CKI, mutations in these
cell-cycle inhibitors have been closely linked with the develop-
ment of numerous tumors [reviewed in 85], supporting the notion
that specific CKI may also function as tumor suppressors [130].
This has lead to another classification for this family of CM,
where each protein is called a multiple tumor suppressor gene,
and is numbered in order of discovery [851. However, at this time,
only p16 is thought to be a tumor suppressor.
The levels of p16 do not oscillate as a function of the cell-cycle.
In contrast, p19 levels do fluctuate, with the highest levels
occurring in S phase [129], while the levels of p15 mRNA and
protein are induced more than 30-fold after TGF-/31 treatment
[29]. TGF-J31 inhibition of proliferation is linked to a variety of
cyclin-kinase inhibitors (Table 3). The current model of how
TGF-131 inhibits proliferation is that p27 is complexed with cyclin
D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 in quiescent cells.
TGF-f31 increases the synthesis of p15, which binds to and inhibits
CDK4 and CDK6, resulting in the displacement of p27 from these
complexes, so that the "free" p27 can then bind to and inhibit
downstream CDK2 complexes [16].
ROLE OF CELL-CYCLE REGULATORY PROTEINS IN THE
KIDNEY
Cell proliferation is one of the hallmarks of many glomerular
diseases such as lupus nephritis, mesangial proliferative glomeru-
lonephephritis, IgA nephritis and even diabetic nephropathy
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Table 4. Expression of cell cycle regulatory proteins in experimental models of renal disease
Animal model
Glomerular disease
Thy! mesangial
proliferative
glomerulonephritis
Passive Heymann
nephritis
Streptozotocin diabetes
Remnant kidney
(5/6 nephrectomy)
Uninephrectomy
Tubulointerstitial disease
Acute ischemia
Ureteral obstruction
Marked mesangial
proliferation [5]
GEC mitosis with
little proliferation:
GEC ploidy [136, 137]
MC hypertrophy;
low-grade
proliferation [138]
Low-grade MC proliferation
[6]; T! proliferation [8]
MC hypertrophy [139]
Cyclin
cyclin Dl [141]
cyclin D2, D3 [141]
11' cyclin A [142]
cyclin A [143]
G1/S cyclins (144]
I cyclin E [145]
G1/S cyclins [146]
11' cyclin Dl [147]
cyclin D2, D3 [147]
¶ ¶ CDK2 [142]¶ CDK4 mRNA [141]
CDK4 protein [142]¶ CDK2 protein [143]
CDK2 activity [144]
CDK4 [143]
CDK2 [144]
CDK4 [1441
¶ CDK2 [146]
CDK4 [145]
CDK2 [146]
CDK4 [146]
C CDK4 [147]
Other cell-cycle
CKI events
C C C p27 [142]
III p21 [142]
I p18 [141]
11' C p21 [143]¶ ¶ p27 [143]
[131]. Furthermore, maneuvers that reduce cell proliferation in
experimental models of renal cell proliferation such as heparin
[1321, low protein diet [133, 134], complement depletion [135] and
blocking specific cytokines [5], reduces glomerular matrix expan-
sion. Similarly, in tubulointerstitial disease such as the remnant
kidney model, early tubular and interstitial cell proliferation is
associated with the later development of fibrosis [81. Although cell
proliferation is ultimately controlled by cell-cycle regulatory pro-
teins, their role in modulating the proliferative activity of renal
cells in kidney disease has only very recently begun to be
established (Tables 4 and 5). Understanding these nuclear mech-
anisms regulating cell proliferation may ultimately have a role in
future therapies.
Activation of Gi cyclins and CDKs in renal disease
Cyclins. The expression and activity of specific cyclins and
cyclin-dependent kinases in glomerular and tubulointerstitial cells
has now been demonstrated to be increased in cell culture
systems, in certain in vivo experimental models, and in renal
development. However, no studies of cyclins and cyclin-depen-
dent kinases in human renal disease have yet been reported.
When quiescent mesangial cells are stimulated to proliferate in
vitro by mitogens, there is an increase in the expression of cyclins
Dl, E and A (Table 5). Furthermore, overexpressing cyclin Dl
decreases the duration of Gi in rat mesangial cells [152], whereas
reducing the expression of cyclin Dl with antisense oligode-
oxynucleotides prevented endothelin-1 induced mesangial cell
proliferation [156]
The normal glomerulus is quiescent [158], and it is therefore
not surprising that 01/S cyclins are not expressed [142]. However,
a marked alteration in the expression of eyclins in vivo have now
been documented in a variety of models of glomerular injury
(Table 4). We and others have studied the Thyi model of
experimental mesangial proliferative glomerulonephritis, which is
induced by the administration an antibody directed against the
Thyl antigen present on rat mesangial cells [159]. This leads to
complement-mediated mesangiolysis, followed by intense mesan-
gial cell proliferation. Mesangial cell proliferation starts at day 2,
peaks at day 5, with resolution of proliferation occurring by day 7.
Our studies demonstrate that infusion of PDGF and bFGF into
normal rats and rats "primed" with low doses of anti-Thyl
antibody induce mesangial cell proliferation and matrix expansion
[160], and administering anti-PDGF antibody or anti-bFGF anti-
body reduces mesangial cell proliferation in vivo in the Thyl
model [5]. Therefore, confirming in vitro observations, we have
clearly demonstrated that PDGF and bFGF mediate mesangial
cell proliferation in vivo.
The onset of mesangial cell proliferation in the Thyl model is
associated with a significant increase in expression of cyclin A
[142]. Yamada et al showed an increase in cyclin Dl in Thyl [141]
and, similar to our findings [142], that the levels for cyclins D2, D3
and E are unchanged. Unlike the Thyl model, mesangial cell
proliferation following capillary hypertension (remnant kidney
model) is associated with an increase in expression for cyclin E
[146, 1611. In contrast to these models of "proliferative" glomer-
ular disease, glomerular diseases that are characterized by a
predominance of cell hypertrophy rather than proliferation, such
as streptozotocin-induced diabetes [161] and uninephrectomy
[146], are not associated with significant increases in the expres-
sion of 01/S phase cyclins.
Cyclins also increase during renal tubular cell proliferation in
vivo. Following acute renal ischemia, the levels of cyclin Dl, but
not cyclins D2 or D3, increase within 24 hours [1621. In renal
tubular cells in vitro, Franch et a! have shown that TGF-l
converts EGF-induced hyperplasia to hypertrophy [1631, and this
was mediated through a decrease in cyclin E-CDK2 activity [1641.
The expression of cyclins during renal development has been
studied by Park and colleagues, who noted that the expression of
cyclins A, B and E decreases immediately after birth in rat
kidneys. In contrast, D-type eyelins are expressed until day 7 after
birth, a period in which glomerulogenesis and tubulogenesis is still
occurring [146]. Although these results are somewhat similar to
Growth characteristic CDK
9
1' p53 [151]
pRb hypo-P [144]
Renal tubular
proliferation
Interstitial proliferation
[140]
p21, p27, p57 [148] pRb hyper-P [145]
p21, p27, p57 [148]
1' 1' p16 [147]
¶ ¶ p21 [147, 149]
¶ I p21 [150]
Abbreviations are: MC, mesangial cell; GEC, glomerular epithelial cell; TI, tubulointerstitial cell; pRb, retinoblastoma protein; no increase; ¶'
mild increase; ¶ ¶, moderate increase; ¶ ¶ ¶, marked increase; C C C, marked decrease; hypo-P, hypophosphorylated; hyper-P, hyperphosphory-
lated; ?, unknown at time of manuscript submission.
GADD45 [150]
¶ ¶ p53 [150]
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Table 5. Expression of cell cycle proteins during mesangial cell
proliferation in vitro
Cytokine Increase Decrease
PDGF cyclins Dl [152, 153] p27 [1541
cyclin E [145]
cyclin A [154]
CDK2 [153, 1541
CDK4 [1521
p21 [1541
bFGF cyclin E [1451 p27 [154]
cyclin A [154]
CDK2 [154]
ET-1 cyclin Dl [153, 155, 156]
CDK4 [153, 156]
TGF-pl p15 [1571 cyclin A [154]
p21 [154, 157] CDK2 [153, 157]
p27 [154] CDK4 [157]
cardiac development shown by Park et a! [165], they do suggest a
potential role for specific cell-cycle proteins in renal development.
Thus, specific cyclins are increased during renal cell prolifera-
tion, and the predominant cyclin expressed may differ depending
on the disease model and type of renal cell involved. This suggests
that this pattern of cyclin expression may be important in deter-
mining and regulating the proliferative response in the kidney.
('yclin dependent kinases. In contrast to many other cell types
where the protein levels of CDK2 remain constant throughout the
cell-cycle [221, quiescent mesangial cells in vitro have a low
abundance of CDK2 protein. However, the protein levels for
CDK2 are markedly increased by PDGF and bFGF during
mesangial cell proliferation in vitro (Table 5). CDK4 activity is
also increased by mitogens (Table 5).
Similar to in vitro observations, the normal rat glomerulus has
low levels of CDK2 expression. However, the onset of mesangial
cell proliferation in the Thyl model is associated with a marked
increase in CDK2 expression [142]. Furthermore, while no kinase
activity for CDK2 can be detected in the normal rat glomerulus,
functional activity for CDK2 (kinase activity) is increased with the
Onset of mesangial cell proliferation in Thyl glomerulonephritis
[142]. By performing immunoprecipitation, we showed that the
kinase activity for CDK2 in Thyl was due to the complexing of
CDK2 with cyclin A, and not cyclin E [142]. The levels for CDK2
are also increased in the remnant kidney model [145, 146]. In
contrast, there is no detectable change in CDK2 expression in
experimental diabetic nephropathy [161] and following unine-
phrectomy [146], in which glomerular cell hypertrophy predomi-
nates and cell proliferation is low grade or minimal. Taken
together, our in vitro and in vivo studies suggest that unlike
non-renal cells where the protein levels for CDK2 are typically
unchanged throughout the cell-cycle, CDK2 is up-regulated in
specific renal diseases. More recently, Dousa and colleagues have
shown that reducing the activity of CDK2 with the inhibitor,
Olomousine, prevents PDGF-induced mesangial cell proliferation
in vitro (personal communication, T. Dousa). CDK2 may there-
fore be a useful target for future therapeutic interventions in
specific renal diseases characterized by mesangial cell prolifera-
tion.
Mitogen-induced mesangial cell proliferation in vitro is associ-
ated with an increase in expression [155] and activity [1561 for
CDK4. The levels for CDK4 increase in acute experimental renal
ischemia in vivo [162]. However, we could not detect any change
in protein expression for CDK4 in experimental diabetes [144],
remnant kidney model (5/6 nephrectomy) [145] and Thyl glomer-
ulonephritis [142] (Table 4). Park et al have also shown that
during rat renal development, CDK2 and CDK4 were expressed
until day 7 after birth [146].
Thus, findings consistent with a central role for specific cyclins
and cyclin-dependent kinases have now been reported in the
development of cell proliferation in a variety of experimental
renal disease models.
Retinoblastoma protein: Determinant of renal cell proliferation
versus hypertrophy. For a cell to proliferate requires that cyclins
and CDKs phosphorylate the retinoblastoma protein (pRb).
Hyperphosphorylated pRb allows cells to exit Gi and enter the S
phase of the cell-cycle [78]. Indeed, the phosphorylation status of
pRb may be central in determining if renal cells proliferate or
hypertrophy in response to injury. Thus, phosphorylation of pRb
is required for PDGF-induced mesangial cell proliferation in vitro
[153]. In contrast, preventing pRb hyperphosphorylation by
TGF-pl [153, 157] or by overexpressing the nonphosphorylated
form of pRb [1561 prevents mitogen-induced mesangial cell
proliferation in vitro. In the normal rat glomerulus in vivo, we have
shown that pRb is hypophosphorylated [161], and mesangial cell
proliferation in the remnant kidney model (5/6 nephrectomy) is
associated with the hyperphosphorylation of pRb [145].
In contrast to cell proliferation where hyperphosphorylation of
pRb is required, hypophosphorylation of pRb is associated with
renal cell hypertrophy. In renal tubular cells in vitro, Franch et a!
showed that maintaining pRb in a hypophosphorylated state was
required for TGF-131 induced cell hypertrophy [163]. In experi-
mental diabetes in vivo, where glomerular hypertrophy is domi-
nant, pRb is also in the hypophosphorylated form [161].
Critical role for cyclin kinase inhibitors in renal disease
p27: A critical regulator in the proliferative response to injuly. We
and others have studied the role of CKI in mesangial cell
proliferation. The cyclin-kinase inhibitors (CKI) have an inhibi-
tory role on the cell-cycle, and are likely major regulators of the
renal cell's proliferative response to injury. Data are accumulating
to suggest a critical role for p27 in maintaining quiescence in
non-renal cells [95, 125]. We have focused on the role of this CKI
in mediating cytokine-induced mesangial cell proliferation. Qui-
escent rat mesangial cells in vitro have high levels of p27, and both
PDGF- and bFGF-induced mesangial cell proliferation is associ-
ated with a dramatic decrease in p27 levels, where the decline in
p27 levels precedes the onset of DNA synthesis [154]. However,
the levels of p27 are always detected in proliferating mesangial
cells (by Western blot analysis), and this likely reflects the fact that
only about 40% of mesangial cells proliferate in response to these
mitogens, and therefore the protein extracts from a proliferating
mesangial cell population comprise both non-proliferating and
proliferating cells [154].
The normal rat glomerulus in vivo also has a high endogenous
expression of p27 [1421. In the Thyl model of glomerulonephritis
the onset of mesangial cell proliferation is associated with a
decline in p27 levels [142], similar to that observed in vitro [154].
The decline in p27 coincides with an increase in functional activity
of CDK2 (kinase activity) [142]. Furthermore, p27 levels are
almost undetectable at the peak of mesangial cell proliferation in
this model (Fig. 8B). Of interest is that the resolution of mesangial
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/ growth/ factors
p27
y
Mesangial cell proliferation
Fig. 7. Proposed cell-cycle events following
mesangial cell injury. Mesangial cell (MC)
injury is associated with the increase in
expression of specific mitogenic cytokines such
as PDGF and bFGF. The onset of MC
proliferation following glomerular injury is
associated with an increase in expression of
cyclin A and cyclin dependent kinase 2
(CDK2). Injury reduces expression of the cyclin
kinase inhibitor p27, which allows for increased
cyclin A-CDK2 activity. These events, and the
increase in expression of the auxilliary DNA
polymerase protein, proliferating cell nuclear
antigen (PCNA), lead to MC proliferation. The
anti-proliferative cytokine TGF-B is expressed
during the peak of MC proliferation. This is
followed by resolution of MC proliferation,
which is associated with normalization of p27
levels and an increase in p21 expression. The
DNA damage due to MC injury causes an
increase in p53 expression, which precedes and
may induce the de novo expression of p2!. p53
may also have a role in MC apoptosis that
occurs in glomerular disease.
cell proliferation in this model is associated with a return of p27
to baseline levels [142].
Based on our in vitro and in vivo results, we have begun to
investigate the functional role of p27 in mesangial cell prolifera-
tion. In rat mesangial cells in vitro we reduced the levels of p27
using antisense oligodeoxynucleotides, and in collaboration with
J.M. Roberts, have studied mesangial cells in vitro derived from
p27 knockout and wild-type mice [154]. These studies have
demonstrated three interesting findings. First, in the absence of
growth factors (serum free conditions), reducing the levels of p27
was not associated with an increase in mesangial cell proliferation.
Second, the onset and magnitude of maximal mesangial cell
proliferation induced by the mitogens PDGF and bFGF were
increased in cells transfected with p27 antisense oligodeoxynucle-
otides compared to mesangial cells transfected with control
oligodeoxynucleotides. Similarly, when FCS was used as a source
of growth factors, the magnitude of proliferation was markedly
increased in mesangial cells derived from p27 knockout compared
to wild-type mice. Third, despite the loss of p2'7, the anti-
proliferative cytokine TGF-/31 reduced mesangial cell prolifera-
tion induced by PDGF and bFGF, suggesting that the inhibitory
action of this cytokine on mesangial cell proliferation does not
solely require p27.
These in vitro and in vivo studies suggest that, in contrast to
non-renal cells [125], p27 alone is not sufficient to maintain
mesangial cell quiescence. Furthermore, lowering the levels of
p27 alone is not sufficient but is required to induce mesangial cell
proliferation. Furthermore, the onset of mesangial cell prolifera-
tion requires both a decrease in p27 levels, and the presence of a
mitogen. These studies therefore support the notion that p27 is a
critical determinant in the mesangial cell's proliferative response
to glomerular injury. The role for p27 in TGF-/31 mediated growth
arrest is discussed below.
p21: Regulator of ongoing renal cell proliferation. Another im-
portant CM in glomerular disease is p21, which is not expressed
in quiescent mesangial cells in vitro and is not detected in the
normal glomerulus in vivo. However, p21 is induced in disease
states, and its expression correlates with the reduction in prolif-
eration. Overexpressing p21 in mesangial cells in vitro inhibits
PDGF-induced proliferation by 60% [152].
There is a de novo expression of p21 in the Thyl model of
experimental mesangial proliferative glomerulonephritis (see p.
1233 in [1421 for color figure). The increase has recently been
confirmed by others [1411. p21 expression in this model coincides
with the resolution of mesangial cell proliferation, suggesting that
p21 may be a critical determinant in the resolution of ongoing
mesangial cell proliferation. Although the mechanisms responsi-
ble for the increase in p21 expression in glomerular disease in vivo
are unknown, we propose two possible mechanisms. First, we have
shown an early increase in p53 expression in Thyl that precedes
the expression of p21 [151]. The increase in p53 may be due to
DNA damage following mesangiolysis or to dysregulated prolif-
eration in this model, which leads to imperfect DNA synthesis
(Ri. Johnson, personal communication). Thus, in the Thyl
model, the increase in p53 may be responsible for the up-
regulation of p21, which in turn leads to the resolution of cell
proliferation (Fig. 7). Second, the de novo expression of p21
following glomerular injury in Thyl glomerulonephritis may relate
to the increase in TGF-f31 expression [166], as this anti-prolifer-
ative cytokine increases the expression of p21 in mesangial cells in
culture [154].
p21 expression is also associated with cell-cycle arrest in
Mesangial cell injury
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tubulointerstitial renal disease. Morrissey and co-workers showed
that unilateral ureteral obstruction is associated with a dramatic
increase in the mRNA levels for p21 [150]. Interestingly, similar to
our observations in the glomerulus, the increase in p21 in the
tubulointerstitium following ureteral obstruction was associated
with an increase in p53 expression, suggesting a possible associa-
tion of p53 and p21 expression. The increase in p53 and p21
correlated with an increase in matrix proteins, and treating rats
with the ACE inhibitor enalapril substantially decreased p53 and
p21 levels, as well as fibrosis in this model [150]. Morrissey et a!
also showed that the increase in p21 following ureteral obstruction
was due to TGF-f31 [150]. Price et al showed that p21 is also
expressed in a variety of other tubulointerstitial renal diseases
including ischemia and cisplatinum injury [149]. Of particular
interest is that the induction of p21 in these two experimental
models is through p53-independent mechanisms [149, 181]. More
recently, Price et al showed that p21 may be required for terminal
differentiation of renal tubule cells during development [167].
Together, these studies provide important data suggesting a
possible role for p21 in both glomerular and tubulointerstitial
disease.
INK4 inhibitors. Very little is known about these CKI in renal
disease. However, Terada et a! showed that mitogen-induced
mesangial cell proliferation could be inhibited in vitro by trans-
fecting mesangial cells with p16 [152]. There is also an increase in
p18 expression in Thyl glomerulonephritis [141].
Why does the glomerular epithelial cell not proliferate in vivo?
In contrast to the mesangial cell and glomerular endothelial
cells, the visceral glomerular epithelial cell or podocyte (GEC)
has little proliferative capacity in vivo, and it has been proposed
that once GEC have developed their differentiated phenotype,
they lose the ability to divide [168]. In most glomerular diseases
the number of GEC remains unchanged. That some GEC prolif-
eration can occur with injury has been documented [136]. In the
experimental passive Heymann nephritis (PHN) model of mem-
branous nephropathy where GEC are the target of complement-
mediated injury, Floege et al have shown that GEC DNA
synthesis occurs, but proliferation is low grade and transient [136].
In addition, Kriz et a! showed that although the GEC have the
capacity to undergo mitosis and even ploidy in vivo under certain
circumstances such as the chronic infusion of bFGF, GEC do not
actually divide (cytokinesis), and the cell number remains un-
changed [137]. More recently, Floege et al have shown that
infusing bFGF into rats with PHN was associated with an in-
creased number of GEC with mitotic characteristics and ploidy,
but the cell number remained unchanged [169]. Thus, GEC have
the ability to synthesize new DNA in vivo, but it is markedly
limited, and thereafter GEC tend to block in the M phase of the
cell-cycle. Taken together, "inadequate" GEC DNA synthesis and
cell division following injury results in an inability of the GEC to
adequately cover the glomerular basement membrane, which
leads to the development of progressive glomeruloscierosis. How-
ever, despite these fundamental observations, the reasons for the
reduced proliferative capacity of the GEC in vivo remains to he
clarified.
Based on the observations in non-renal cells in vitro, we
postulated that the reduced proliferative capacity of the GEC in
vivo might reflect an overexpression of cyclin kinase inhibitors. To
explore this question, we studied the expression of specific
Fig. 8. Expression of p27 in experimental glomerular disease. There is an
increase in p27 following glomerular epithelia! cell injury in the passive
Heymann nephritis model CA), where cell proliferation is absent. In
contrast, there is a decrease in p27 levels by Western blot analysis in Thyl
g!omerulonephritis (B), which coincides with the peak in mesangia! cell
proliferation. (Permission to republish this Figure is by the International
Society of Nephrology; Kidney mt 50:1230—1239, 1996).
cell-cycle proteins in normal rats and rats with PHN. Our first
observation was that complement-mediated GEC injury in vivo is
associated with a dramatic increase in the expression for the cyclin
kinase inhibitor p27 (Fig. 8A) [143]. This contrasts with the
decrease in p27 levels in experimental mesangial proliferative
glomerulonephritis (Thyl model; Fig. 8B) [142]. Our second
observation was that GEC injury in vivo was also associated with
a marked increase in the expression of the CM p21 [143]. We
were also able to demonstrate that p2l and p27 associates with
cyclin A-CDK2 in protein lysates from isolated glomeruli of rats
with PHN, thereby reducing the functional activity of CDK2
(kinase activity) [143]. Furthermore, giving bFGF to rats with
PHN was associated with a decrease in p21 expression [143]. Thus,
although the mechanisms responsible for the low proliferative
capacity of the GEC in disease remain to be fully elucidated, our
studies suggest that this may be due in part to the up-regulation of
the cyclin kinase inhibitors p21 and p27 following injury to the
GEC in vivo. We recently demonstrated that TGF-32 and j33
isoforms and the TGF-j3 type I and II receptors are increased in
PHN, and the increase was complement dependent [170]. Because
TGF-p is anti-proliferative to the GEC in vitro [171] and TGF-J3
up-regulates p21 expression in certain non-renal cells in vitro [88],
the increase in TGF-13 expression in disease may be responsible in
part for the low proliferative capacity by the GEC in vivo, and this
may be mediated in part through p21. What still remains unclear
is why, when the GEC does successfully undergo DNA synthesis,
it is associated primarily with polyploidy, or "arrests" in M phase
of the cell-cycle. It seems possible that this may involve the M
phase cyclins that are required for mitosis and cytokinesis (cell
division). Further studies are required to answer these questions.
TGF-j3 and renal cell proliferation
TGF-13 is a cytokine with diverse effects on matrix proteins and
cell growth [172] and is of interest to nephrologists because it is
increased in a variety of renal diseases [172, 173]. TGF-13 tends to
inhibit renal cell proliferation in vitro [1731. Sterzel's group
recently showed that TGF-f31 inhibits mesangial cell proliferation
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by blocking GuS transition [153], and this involved maintaining
pRb in a hypophosphorylated state. TGF-pl reduces the expres-
sion of cyclin A [154] but not cyclin Dl [1531 in mesangial cells
(Table 5). TGF-j31 does not affect the levels of CDK2 [153, 154],
or CDK4 [153] in mesangial cells. However, TGF-J31 inhibits the
functional activity of CDK2 and CDK4 [153, 157]. This would
suggest a role for the cyclin kinase inhibitors in decreasing the
functional activity of the CDKs, and thereby maintaining pRb in
the hypophosphorylated (growth inhibitory) state.
We and others have also been interested in understanding how
cyclin kinase inhibitors mediate the reduction of mesangial cell
proliferation by TGF-131 in vitro. An interesting finding was that
TGF-pl prevented the decrease in p27 expression following
PDGF and bFGF stimulation of mesangial cells in vitro [154]. This
initial observation raised the possibility that p27 may be critical in
TGF-!31 mediated inhibition of mesangial cell proliferation. To
explore this further, we reduced the expression of p27 with
specific oligodeoxynucleotides, and showed that PDGF and bFGF
induced rat mesangial cell proliferation was still prevented by
TGF-f31 [154]. Additional studies were performed in mesangial
cells in vitro derived from p27 knockout mice and wild-type mice.
Similar to rat mesangial cells, TGF-f31 inhibited FCS-induced
mouse mesangial cell proliferation in cells lacking p27 [154].
Taken together, these studies suggest that p27 alone is not
required for the inhibition of mesangial cell proliferation by
TGF-131 in vitro. We [154] and others [157] have shown that
TGF-131 increases the expression of the cyclin kinase inhibitor p21
in cultured mesangial cells. Furthermore, p15 is increased during
TGF-pl inhibition of mesangial cell proliferation [157]. There-
fore, TGF-j31 may inhibit mesangial cell proliferation through
many cell-cycle pathways (Table 5). TGF-pl expression is also
associated with the induction of p21 in vivo in the Thyl [142] and
PHN [143] models, as well as in the tubulointerstitial disease
caused by ureteral obstruction [150].
TGF-/31 may also induce renal hypertrophy [174, 175]. This may
be linked to cell-cycle proteins. Franch et al showed that TGF-131
converts EGF-induced renal tubular cell hyperplasia to hypertro-
phy by inhibiting EGF-mediated phosphotylation of pRb [1631.
This was not associated with changes in cyclin D-CDK4 activity
[176] or cyclin E levels, but rather a decrease in cyclin E-CDK2
activity. More recently, Franch, Alpern and Preisig showed that
the effect of TGF-/31 was independent of p27 [164]. In proximal
renal tubule cells in vitro, it has recently been shown that
angiotensin II mediates hypertrophy through two mechanisms: a
TGF-f31-p15 pathway, and a TGF-f31-independent-p21 pathway
[177]. In LLC-PK1 cells, angiotensin II induced hypertrophy also
depends on TGF-pl, and Wolf and Stahl have shown that this
effect may be mediated through an increase in p27 levels [178].
TGF-J31 causes mesangial cell hypertrophy in vitro [174] and
Sharma et a! [179] and others [1801 have shown that TGF-pl
mediates glomerular hypertrophy in experimental diabetes in vivo.
In the normal quiescent rat glomerulus in vivo, pRb is hypophos-
photylated and this state was maintained in experimental diabe-
tes, suggesting that pRb may also be regulated by TGF-131 in vivo.
CONCLUSION
In summary, our understanding of the role of cell proliferation,
or on some cases its absence, continues to expand. We now
recognize important structural and functional consequences that
derived from both an increase in the proliferative rate of cells such
as mesangial and renal tubular cells, and from the failure of other
cells such as GEC to proliferate at all in response to various
mechanisms of injury. Paradoxically, both of these scenarios
appear to lead to sclerosis and renal failure, providing compelling
reasons to better understand how the cell-cycle is regulated in
kidney cells. The past decade has witnessed major advances in
understanding the plethora of growth factors and cytokines that
stimulate or inhibit cell proliferation. It is the challenge of the
decade ahead to move our studies to the intracellular level. The
relatively recent discovery of cell-cycle regulatory proteins and
their inhibitors offers the opportunity to study the cellular mech-
anisms of kidney disease at a new level; already the data available
and reviewed here establish that alterations in these proteins are
likely central in determining the renal response to injury and
repair.
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APPENDIX
Abbreviations are: CDK, cyclin dependent kinase; CKI, cyclin kinase
inhibitor; i21, 21CIP 1. WAF!. SD!!, CAP!; 27, p27K!Pl; PDGF, platelet-
derived growth factor; bFGF, basic fibroblast growth factor; TGF-/3,
transforming growth factor-13; pRb, retinoblastoma protein; Thyl, Thyl
model of experimental mesangial proliferative glomerulonephritis; GEC,
visceral glomerular epithelial cell.
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